valsartan has been researched along with Amentia in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, WS; Lin, CL | 1 |
| Hirsh Raccah, B; Matok, I; Muszkat, M; Perlman, A | 1 |
| Feng, GF; Han, H; Hu, XD; Liu, Y; Qian, YH; Shi, LL; Yang, WN | 1 |
| Cannon, JA; Chen, F; Gong, J; Jhund, PS; Kristensen, SL; Køber, L; Lefkowitz, MP; McMurray, JJ; Packer, M; Rouleau, JL; Shen, L; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR | 1 |
1 trial(s) available for valsartan and Amentia
| Article | Year |
|---|---|
Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction.
Topics: Aged; Aminobutyrates; Amnesia; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Confusion; Delirium; Dementia; Disorders of Excessive Somnolence; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Proportional Hazards Models; Stroke Volume; Tetrazoles; Valsartan | 2017 |
3 other study(ies) available for valsartan and Amentia
| Article | Year |
|---|---|
Angiotensin Receptor-neprilysin Inhibitor Versus Renin-angiotensin System Inhibitor for Dementia Risk in Patients With Heart Failure.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Dementia; Enzyme Inhibitors; Heart Failure; Humans; Neprilysin; Renin-Angiotensin System; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Cognition- and Dementia-Related Adverse Effects With Sacubitril-Valsartan: Analysis of the FDA Adverse Event Report System Database.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cognition; Cognition Disorders; Dementia; Drug Combinations; Female; Heart Failure; Humans; Incidence; Male; Neprilysin; Retrospective Studies; Stroke Volume; Tetrazoles; United States; United States Food and Drug Administration; Valsartan | 2018 |
The effects of valsartan on cognitive deficits induced by aluminum trichloride and d-galactose in mice.
Topics: Acetylcholinesterase; Aluminum Chloride; Aluminum Compounds; Animals; Cerebral Cortex; Chlorides; Cognition Disorders; Dementia; Disease Models, Animal; Galactose; Glutathione Peroxidase; Hippocampus; Malondialdehyde; Maze Learning; Memory Disorders; Mice; Nootropic Agents; Oxidative Stress; Random Allocation; Superoxide Dismutase; Tetrazoles; Valine; Valsartan | 2014 |